Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
Clinical trial NCT05162066 · TERMINATED
Trial details
- NCT number
- NCT05162066
- Sponsor
- BioCryst Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-18
- Primary completion
- 2022-09-23
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.